Enveda vs Valo Health (2026)
Nature's chemistry is where Enveda starts, and patient data is where Valo Health starts. Both use AI to find small molecule medicines and both keep pipelines of their own, but they part ways on who takes a molecule into people. Enveda's PRISM model, trained on 1.2 billion mass spectra, reads the chemistry of plants, microbes and the human body and predicts a structure in about half a second, and an automated laboratory screens what it finds before chemists refine the best into oral medicines. It runs its own trials: ENV-294 is in Phase 2a for atopic dermatitis and asthma after Phase 1b results in March 2026, ENV-308 reported Phase 1 results in 88 volunteers in August 2026, and ENV-6946 entered Phase 1 for inflammatory bowel disease. Venture rounds, most recently a $311 million Series E, pay for that work. Valo Health begins with patients rather than molecules. Causal inference and statistical genetics run over more than 17 million de identified records to find targets, and its chemistry loop then designs small molecules against them. Valo advances early research and hands clinical development to partners such as Novo Nordisk and Merck KGaA, keeping royalties under what it calls success based economics. Its one clinical readout, for OPL-0401, came from a molecule outside the platform and missed its endpoints. An investor or partner following clinical stage oral medicines discovered from natural chemistry will look to Enveda. A drug maker that wants a discovery partner to find and check targets in human data and then hand over candidates will find Valo built for that arrangement.
- Molecules that already exist in plants, microbes or the human body are the preferred starting point.
- Clinical data on oral candidates in dermatology, asthma or metabolic health matters now.
- Reading structures from mass spectrometry data is the technology that matters most.
- The company running discovery should also run its own trials.
- Targets should be found and checked in large scale patient records first.
- The partner wants to lead clinical development itself.
- Success based economics with royalties suit the deal.
- Obesity, diabetes or Parkinson's disease is the area of work.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Enveda and Valo Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Enveda | Valo Health |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | Not recorded |
| Headquarters | Boulder, Colorado, United States | Lexington, Massachusetts |
| Website | enveda.com | valohealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
Enveda finds medicines in natural chemistry with PRISM, a model trained on 1.2 billion mass spectra, and develops them itself, with three oral candidates in clinical trials.
Source: AI Health Index, October 2026
Valo Health turns long patient histories into ranked disease targets, designs small molecules against them, and partners programs with drug companies that lead clinical development.
Source: AI Health Index, October 2026
Questions buyers ask
Which of Enveda and Valo Health has platform discovered molecules in human trials?
Enveda does: ENV-294 and ENV-308 were both discovered with PRISM, and ENV-294 reported Phase 1b results before entering Phase 2a. Valo has no platform derived candidate in a clinical study, and its Phase 2 readout came from a molecule that predates the platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
What data does each start from, Enveda or Valo Health?
Enveda trains on mass spectra, about half from public metabolomics repositories and half from its own laboratory, and builds a library of plant molecules. Valo starts from de identified patient records, some with 20 to 30 year histories and linked biobank samples, plus multimodal data from nference. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
How do Enveda and Valo Health fund their pipelines?
Enveda raises venture money for its own programs, most recently $311 million in September 2026. Valo pairs its pipeline with partnerships that pay near term and milestone sums, such as Novo Nordisk's agreement covering up to 20 programs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 13, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Enveda is based in Boulder, Colorado, with a second entity in Hyderabad, and has raised more than $845 million. Valo Health works from Lexington, Massachusetts. Neither sells software, and Enveda publishes no partnering terms.